ARTICLE | Company News
AbbVie, Xynomic Pharmaceuticals deal
March 3, 2017 7:48 PM UTC
Xynomic received exclusive, worldwide rights to develop and commercialize oncology candidate abexinostat from AbbVie. Xynomic said it plans to start Phase III trials of the histone deacetylase (HDAC) ...
BCIQ Target Profiles